Skip To Main Content
Lea Barfod on Muck Rack

Lea Barfod

As seen in: Nature, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lea

Contact Lea, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Epitope-selective vaccine designs to elicit protective antibodies against the Plasmodium falciparum circumsporozoite protein

|
By Mohammad mehdi Naghizadeh, Yevel Flores-Garcia, Gregory Martin, Ebenezer Addo Ofori, Jordan L. Plieskatt, Fabien Cannac, Randall S. MacGill, Morten Nielsen, Emily Locke, C. Richter King, Kazutoyo Miura, Ashley Birkett, Adam F. Sander, Kristin Skogstrand, Lea Barfod, Nis Borbye-Lorenzen, Ian Wilson, Andrew Ward, Fidel Zavala, Michael Theisen, Reem Moskovitz, Sayit Mahmut Erdogan, Lorraine A. Soisson, Berenice Salgado-Jimenez
| Nature Verified
Abstract P. falciparum (Pf) malaria is a major cause of morbidity and mortality in sub-Saharan Africa. Recently introduced malaria vaccines, RTS,S/AS01 and R21/Matrix-M, are effective in preventing infection, but their efficacy declines over time. To address this challenge, next-generation vaccine candidates have been designed to improve the functional immunogenicity to the circumsporozoite protein (PfCSP). In this study, we tested multiple hypotheses for improved vaccine design.
Open in Who Shared Issue with article?

Cryo-EM led analysis of open and closed conformations of Chagas vaccine candidate TcPOP - Nature Communications

|
By Francisco J. Olmo, Timothy J. Ragan, Valeria Calvaresi, Claudia Lancey, Mahya Assadipapari, Weston Struwe, John Kelly, Lea Barfod
| Nature Verified
Abstract Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, remains a significant global public health concern. Despite its profound health impact in both endemic and non-endemic areas, no vaccine is available, and the existing therapies are outdated, producing severe side effects. The 80 kDa prolyl oligopeptidase of Trypanosoma cruzi (TcPOP) has been identified as a leading candidate for Chagas vaccine development.
Open in Who Shared Issue with article?

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex - Nature Communications

|
By Barnabas G Williams, Doris Quinkert, Robert J. Ragotte, Lea Barfod, Alexander Douglas, Randall S. MacGill, Kazutoyo Miura, Carole Long, Matthew Higgins, Amelia M. Lias, Cecilia Carnrot, Amy R. Noe, Hannah Davies
| Nature Verified
Abstract Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR) to form an essential heterotrimeric “RCR-complex”. We investigate whether RCR-complex vaccination can improve upon RH5 alone.
Open in Who Shared Issue with article?
See all 4 articles